Spyre Therapeutics, Inc.
SYRE
Updated: 23/09/2026, 20:28:50
Spyre Therapeutics, Inc. is a biotechnology firm operating at the preclinical stage, dedicated to creating innovative treatments for individuals afflicted with inflammatory bowel disease (IBD). Among its pipeline candidates is SPY001, a human monoclonal immunoglobulin G1 antibody specifically engineered to target and bind with the a4ß7 integrin. This particular therapy is under development for addressing both ulcerative colitis and Crohn's disease, two forms of IBD. Furthermore, Spyre Therapeutics is advancing SPY002, another human monoclonal antibody that aims to interact with tumor necrosis factor-like ligand 1A (TL1A). A synergistic approach is also being explored with SPY120, a compound that merges the anti-a4ß7 action of SPY001 with the anti-TL1A activity of SPY002. All these programs are currently undergoing preclinical evaluation. Beyond these, the company's early-stage portfolio encompasses several additional promising candidates: SPY003, an anti-IL-23 monoclonal antibody; SPY004, a monoclonal antibody with a novel mechanism of action; SPY130, which combines anti-a4ß7 and anti-IL-23 antibodies; and SPY230, a dual antibody therapy featuring anti-TL1A and anti-IL-23 components. Originally incorporated in 2013, the organization was previously known as Aeglea BioTherapeutics, Inc., before rebranding to Spyre Therapeutics, Inc. in November 2023. Its headquarters are located in Waltham, Massachusetts.
No summaries found.
- Share price
- $87.12
- Market cap
- $7.57B
- Exchange
- NASDAQ
- Currency
- USD
- CEO
- Cameron Turtle
- Employees
- 125
- IPO date
- 07/04/2016
- Beta
- 3
- Last dividend
- $0.00
- Day range
- $86.30 – $91.56
- 52-week range
- $15.49 – $110.18
- 1-day performance
- -5.27%
- 1-year performance
- 462.45%
- Current drawdown (1Y)
- -20.92%
- CIK
- 0001636282
- CUSIP
- 00773J202
- ISIN
- US00773J2024
- Created
- 07/12/2025, 14:28:16
- Last update
- 23/09/2026, 20:28:50
Track Spyre Therapeutics, Inc. with an AI analyst
See which prediction-market events move SYRE, how its filings map to real-world exposure, and what 12 AI strategies are doing with positions like it.
Free forever to follow AlphaBrain’s AI strategies. No card required.
Spyre Announces Potential Best-in-Class SPY002 (anti-TL1A) Part A Induction Results from SKYLINE Trial in Moderate-to-Severe Ulcerative Colitis Patients
GlobeNewsWire • STOCK • 15/06/2026, 10:00:00
Spyre Therapeutics Announces Grants of Inducement Awards
GlobeNewsWire • STOCK • 05/06/2026, 18:01:00
SYRE Completes Enrollment in SKYWAY Basket Study on SPY072, Stock Up
Zacks Investment Research • STOCK • 04/06/2026, 14:01:20
Spyre Therapeutics Announces Completion of Enrollment in SKYWAY Basket Trial Evaluating SPY072 (anti-TL1A) in RA, PsA, and axSpA
GlobeNewsWire • STOCK • 03/06/2026, 10:00:00
Spyre Therapeutics to Participate in Upcoming June Investor Conferences
GlobeNewsWire • STOCK • 26/05/2026, 18:10:00
SYRE Stock Jumps More Than 70% in a Month: What Is Driving This Rally?
Zacks Investment Research • STOCK • 23/04/2026, 15:36:24
Spyre Therapeutics Announces Pricing of Upsized $403.0 Million Public Offering of Common Stock
GlobeNewsWire • STOCK • 15/04/2026, 00:38:00
Spyre Therapeutics (NASDAQ: SYRE) Soars on Positive Phase 2 Ulcerative Colitis Trial Results
Market Data • Market Data • 14/04/2026, 12:12:09
Spyre Therapeutics: Strong SPY001 Data Set Up A Catalyst-Rich 2026
Seeking Alpha • STOCK • 14/04/2026, 09:45:06
Spyre Therapeutics Announces Proposed Public Offering of its Common Stock
GlobeNewsWire • STOCK • 13/04/2026, 18:46:00
Spyre Therapeutics, Inc. (SYRE) Discusses SPY001 Part A Induction Topline Results From SKYLINE Trial in Moderate-to-Severe Ulcerative Colitis Transcript
Seeking Alpha • STOCK • 13/04/2026, 17:21:47
Spyre Announces Potential Best-in-Class SPY001 Part A Induction Results from SKYLINE Trial in Moderate-to-Severe Ulcerative Colitis Patients
GlobeNewsWire • STOCK • 13/04/2026, 09:00:00